PMV Pharmaceuticals, Inc. (PMVP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, PMV Pharmaceuticals reported revenue of $0. Net income was -$77.7M, or -$1.48 per diluted share. Operating activities generated -$73.6M of cash, leaving -$73.6M of free cash flow. At fiscal year end, PMV Pharmaceuticals held $116.6M in total assets against $11.8M in total liabilities, including $38.0M of cash and equivalents.
Open the full interactive PMV Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
PMV Pharmaceuticals Key Stats
| Share Price | $1.35 |
|---|---|
| Market Cap | $72.1M |
| 52-Week Range | $1.02 – $1.80 |
| Shares Outstanding | 53.4 million (basic, 2026 Q2) |
PMV Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$34.9M | -$58.3M | -$77.0M | -$80.1M | -$85.4M | -$86.2M |
| Pre-Tax Income | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$74.8M | -$79.9M |
| Income Tax | $6,000 | $23,000 | -$9,000 | $2,000 | -$16.1M | -$2.2M |
| Net Income | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$58.7M | -$77.7M |
| Diluted EPS | -$2.40 | -$1.28 | -$1.61 | -$1.44 | -$1.14 | -$1.48 |
PMV Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$21.1M | -$18.0M | -$18.0M | -$18.1M |
| Diluted EPS | -$0.40 | -$0.34 | -$0.34 | -$0.34 |
PMV Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $361.4M | $172.5M | $108.3M | $37.7M | $40.9M | $38.0M |
| Current Assets | $364.8M | $301.3M | $247.0M | $207.4M | $175.7M | $115.2M |
| Total Assets | $365.5M | $331.6M | $270.3M | $252.2M | $191.3M | $116.6M |
| Current Liabilities | $6.4M | $12.2M | $10.8M | $14.0M | $14.4M | $11.4M |
| Total Liabilities | $6.4M | $23.0M | $24.3M | $26.5M | $15.2M | $11.8M |
| Shareholders' Equity | $359.1M | $308.6M | $246.0M | $225.7M | $176.1M | $104.7M |
PMV Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$32.7M | -$46.6M | -$63.8M | -$55.7M | -$51.3M | -$73.6M |
| Cash From Investing | $27.9M | -$143.6M | -$1.4M | -$50.5M | $53.4M | $70.2M |
| Cash From Financing | $293.0M | $2.0M | $958,000 | $35.6M | $313,000 | $505,000 |
| Free Cash Flow | -$32.9M | -$47.9M | -$71.7M | -$56.6M | -$51.9M | -$73.6M |
Figures from PMV Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full PMV Pharmaceuticals financials page for every line item.
PMV Pharmaceuticals Company Profile
| Ticker | PMVP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001699382 |
Frequently Asked Questions
What was PMV Pharmaceuticals' revenue in fiscal 2025?
PMV Pharmaceuticals (PMVP) reported revenue of $0 for fiscal 2025.
What is PMV Pharmaceuticals' annual revenue history?
PMV Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was PMV Pharmaceuticals' net income in fiscal 2025?
PMV Pharmaceuticals reported net income of -$77.7M for fiscal 2025.
What was PMV Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
PMV Pharmaceuticals' diluted EPS was -$1.48 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did PMV Pharmaceuticals generate in fiscal 2025?
PMV Pharmaceuticals generated -$73.6M of free cash flow in fiscal 2025.
What was PMV Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), PMV Pharmaceuticals reported revenue of $0.
How many shares of PMV Pharmaceuticals are outstanding?
PMV Pharmaceuticals reported a weighted average of 53.4 million basic shares outstanding in 2026 Q2.
What is PMV Pharmaceuticals' market cap?
Based on its latest closing price, PMV Pharmaceuticals (PMVP) has a market capitalization of about $72.1M.
When does PMV Pharmaceuticals' fiscal year end?
PMV Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is PMV Pharmaceuticals headquartered?
PMV Pharmaceuticals lists its business address in Princeton, New Jersey in its SEC filings.